SLC5A2 and type 2 diabetes mellitus: In T2D group, the anti-diabetic medications used were metformin in 97 (51.6%), sulfonylurea in 78 (40.4%), thiazolidinediones in 21 (10.6%), DPP-4 inhibitors in 52 (27.7%), SGLT-2 inhibitors in 17 (9.0%), GLP-1 agonists in six (3.2%), and insulin in 14 (6.9%) patients.